HM 279
Alternative Names: HM-279Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Carna Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Dec 2024 HM 279 is available for licensing as of 18 Dec 2024. https://www.carnabio.com/english/discovery/partnering.html
- 23 Oct 2024 Preclinical trials in Cancer in Japan (PO)
- 23 Oct 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)